Press "Enter" to skip to content

Glenmark gets tentative USFDA nod for prostate cancer treatment drug

Glenmark Pharmaceuticals Inc USA has been granted tentative approval by the United States Food and Drug Administration for Abiraterone Acetate tablets USP in the strength of 250 mg, the company said in a BSE filing on Wednesday.

Original source:

Also Read:   New 3D-printed device may cut chemotherapy's side effects